Magellan Health to Present at Barclays Select Series Biosimilars Symposium

SCOTTSDALE, Ariz.--()--Magellan Health, Inc. (NASDAQ: MGLN) announced today that Mostafa Kamal, chief executive officer of Magellan Rx Management, the company’s pharmacy benefit management division, will participate in a panel discussion at the Barclays Select Series Biosimilars Symposium in New York on Wednesday, October 7, 2015 from 8:45-10:15 a.m. Eastern. The panelists will discuss the topic “Determining Access, Driving Acceptance: Biosimilars’ Journey through the Pharmaceutical Supply Chain.”

About Magellan Health: Headquartered in Scottsdale, Ariz., Magellan Health, Inc. is a leader in managing the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits and other specialty areas of healthcare. Magellan develops innovative solutions that combine advanced analytics, agile technology and clinical excellence to drive better decision making, positively impact health outcomes and optimize the cost of care for the members it serves – all within a customer-first culture. Magellan’s customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies, third-party administrators, consultants and brokers. For more information, visit MagellanHealth.com.

Contacts

Magellan Health, Inc.
Media Contact:
Colleen Flanagan Johnson, 860-507-1923
cefjohnson@magellanhealth.com
or
Investor Contact:
Renie Shapiro Silver, 877-645-6464
rshapiro@magellanhealth.com

Release Summary

Magellan Health announced today that Mostafa Kamal, CEO of Magellan Rx Management, will participate in a panel discussion at the Barclays Biosimilars Symposium in New York on October 7, 2015.

Contacts

Magellan Health, Inc.
Media Contact:
Colleen Flanagan Johnson, 860-507-1923
cefjohnson@magellanhealth.com
or
Investor Contact:
Renie Shapiro Silver, 877-645-6464
rshapiro@magellanhealth.com